HOME >> BIOLOGY >> NEWS
Preclinical study shows chronic stress agitates ovarian cancer; reducing stress slows tumor growth

Houston -- When mice with ovarian cancer are stressed, their tumors grow and spread more quickly, but that effect can be blocked using a medication commonly prescribed for heart disease, according to a preclinical study by researchers at The University of Texas M. D. Anderson Cancer Center.

The finding, published in the journal Nature Medicine, now available on-line, provides the first measurable link between psychological stress and the biological processes that make ovarian tumors grow and spread. Specifically, the researchers showed that stress hormones bind to receptors directly on tumor cells and, in turn, stimulate new blood vessel growth and other factors that lead to faster and more aggressive tumors.

"This study provides a new understanding of how chronic stress and stress factors drive tumor growth," says Anil Sood, M.D., associate professor of gynecologic oncology and cancer biology and director of ovarian cancer research.

In fact, when the researchers blocked the stress hormone receptors in their experimental system using a heart disease drug called propranolol, also known as a "beta blocker," they were able to stop the negative effects of stress on tumor growth. The researchers used the beta blocker because the same hormone receptors, called beta adrenergic receptors, are found in the heart and normally work to maintain blood flow.

"The concept of stress hormone receptors directly driving cancer growth is very new," says Sood, the study's senior author. "Not much had been known about how often these receptors are expressed in cancer, and more importantly, whether they had any functional significance. Our research opens a new area of investigation."

The research began when Sood and his colleague Susan Lutgendorf found an association between ovarian cancer patients who reported high levels of stress in their lives and an increase in a factor that stimulates blood vessel growth in tumors. By contrast, patients who had more soc
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
23-Jul-2006


Page: 1 2 3

Related biology news :

1. Preclinical study links gene to brain aneurysm formation
2. Preclinical study of a new brain tumor therapy
3. New study warns limited carbon market puts 20 percent of tropical forest at risk
4. Clones on task serve greater good, evolutionary study shows
5. Pollution causes 40 percent of deaths worldwide, study finds
6. A study by the MUHC and McGill University opens a new door to understanding cancer
7. New study suggests Concord grape juice may provide protection against breast cancer
8. In limiting life span, study finds booming bacteria innocent
9. Multicenter study nets new lung tumor-suppressor gene
10. MIT study: Maturity brings richer memories
11. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study

Post Your Comments:
(Date:11/4/2014)... --   3D scanner developer ... Fuel3D , a developer of 3D scanning solutions, today ... million (£4 million). This funding builds on the company,s initial ... paves the way for the commercial launch of the company,s ... was led by Chimera Partners and will be used to ...
(Date:11/4/2014)... 2014   Neurotechnology , a provider of ... latest version of its fingerprint matching algorithm has ... evaluation organized by NIST. The MINEX test ... INCITS 378 fingerprint standard template format. MINEX compliance ... in the United States ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
(Date:11/21/2014)... 2014 Deep Research Report on ... professional and in-depth research report on the Sodium ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... NEW YORK and SAN DIEGO ... CYTX ), today announced that President and CEO Marc Hedrick ... 2014. DATE:   Thursday, December 4, 2014 ... LINK:     Click here or paste this URL into ... is recommended that investors pre-register to save time and receive ...
(Date:11/18/2014)... Cord Blood Registry® (CBR®) announces that ... World Stem Cell Summit, the largest global meeting of stem ... Cell Summit will be held December 3-5 at the Marriott ... The World Stem Cell Summit aims ... therapies, convening the most prominent figures in the field to ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3
Cached News: